CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
HCP0910 and HGP1011drug
Likely dose
HCP0910 and HGP1011 250 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02441114
NCT02441114Phase 1Completed
CompareCT.gov

A Pilot Study to Investigate Pharmacokinetic Characteristics After Co-administration of HCP0910 and HGP1011

Seoul National University Hospital·interventional·Posted May 12, 2015·Updated Jan 11, 2017

In Brief

A Phase 1 clinical trial evaluating HCP0910 and HGP1011 for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone, salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250 diskus) and HGP1011 (Spiriva capsule for inhalation) which are prescribed concomitantly for the patients with chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 12, 2015
Enrollment StartJul 1, 2015
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.1 years ago

Interventions

HCP0910 and HGP1011drug

Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))